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We report our experience in the management of patients with carcinosarcoma of the ovary, a rare but aggressive variant of ovarian
cancer. Forty patients were treated at a single centre, which is the largest reported series. The median age at diagnosis was 65 years
(range 45–86) and the median Karnofsky performance (KP) status was 70. Thirty-two patients (80%) presented with FIGO stage III
or IV disease. Twenty-four had heterologous and 14 homologous carcinosarcoma on review of histopathology, but there was no
significant difference in survival between these groups (P¼0.28). Twenty-seven of the 40 patients had bulk residual disease present
after surgery and this was associated with a worse prognosis (P¼0.045). Chemotherapy was given to 32 patients (80%) of whom 26
(81%) received platinum-based regimens. Of these 32 patients, three (9.4%) achieved a complete response (CR), 10 (31%) a partial
response (PR), five (16%) had stable disease, 10 (31%) had progressive disease and four were not assessable. Of the 19 patients who
had a CR, PR or stable disease after chemotherapy or were unevaluable (stage Ic), the median survival was 29.6 months. Currently,
seven patients are still alive although one has cancer. The overall censored median survival was 8.7 months after a median follow-up
of 34 months, and the 1- and 5-year survival were 40 and 7.5%, respectively.
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Carcinosarcomas are rare tumours and pathologically consist of a
mixture of malignant epithelial and malignant mesenchymal
components. They can occur throughout the female genital tract
but are found most commonly in the uterus (Newlands and
Paradinas, 1995). Ovarian carcinosarcomas are very rare and
account for only o1–2% of all malignant ovarian tumours
(Iakovleva and Shendereva, 1978; Chang et al, 1995; Melilli et al,
1999). Consequently, their behaviour and management is con-
troversial as most centres only treat small numbers over many
years. A previous study from our centre (Prendiville et al, 1994)
reported on 20 patients from the 1980s who were mainly treated
with surgery and nonplatinum-based chemotherapy.
Macroscopically the tumours are solid and/or cystic, fleshy and
haemorrhagic and frequently spread beyond the ovary and over
peritoneal surfaces by the time of surgery. The malignant
mesenchymal component of the tumour is described as hetero-
logous or homologous. Heterologous elements are tissues not
normally found in the ovary, for example, cartilage, bone, smooth
or striated muscle and adipose tissue. If the sarcomatous part
contains elements that resemble endometrial stromal sarcoma,
fibrosarcoma or leiomyosarcoma (‘homologous’ to the Mullerian
duct system), then it is described as homologous.
The stage classification used for carcinosarcoma of the ovary is
the same FIGO system that is applied to the other ovarian
adenocarcinomas. In comparison with the more common ovarian
carcinomas, the response to therapy and overall survival are poor
with median survivals of 4–14 months (Hanjani et al, 1983; Terada
et al, 1989; Prendiville et al, 1994; Chang et al, 1995), although this
may be confounded to some extent by the higher FIGO stage
(Hanjani et al, 1983; Morrow et al, 1984). We report a retrospective
review of the demography, management and outcome of 40
patients treated for carcinosarcoma at this institute over the last 10
years and compare this to the published literature.
MATERIALS AND METHODS
Between January 1991 and January 2001, 47 patients with the
diagnosis of carcinosarcoma of the ovary were identified through
medical records, the ovarian cancer database or by the department
of histopathology. Seven of these patients were excluded from
analysis because upon review it was unclear if their tumour had
arisen in the ovary or elsewhere in the gynaecological tract. All
patients had their tumour tissue reviewed by a specialist
oncological histopathologist, and in all cases the stage of disease
was calculated from the operative findings at diagnosis, a staging
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lCT scan of the abdomen and pelvis (with and without contrast)
and a chest radiograph.
The case notes were reviewed and information regarding patient
demography, presenting symptoms and signs, FIGO stage,
histology, subsequent management and response to treatment
were recorded and transferred to a database. All intervals were
calculated from the date of operation. Survival statistics were
calculated by a statistician who generated Kaplan–Meier curves.
RESULTS
Patients
The age at operation ranged from 45- to 86 years with a median age
of 65, which is similar to previous studies (Prendiville et al, 1994;
Chang et al, 1995). The Karnofsky performance (KP) status ranged
from 30 to 90 with a median of 70. The FIGO stage at first
chemotherapy is shown in Table 1 and although patients presented
in all four stages, 80% (32 patients) presented with advanced FIGO
stage III or IV disease. In one patient, the initial stage was
unknown because she was only referred on relapse. Twenty-seven
patients had bulk residual disease (42cm) left post initial surgery,
nine had microscopic residual disease (o2cm) and four had no
residual disease detectable. The survival for patients with no bulk
residual disease post surgery was significantly better than those
with bulk residual disease (P¼0.045) and the survival curves are
shown in Figure 1.
Histopathology
Twenty-four of the patients were found to have heterologous
elements and 14 had homologous carcinosarcoma on review of the
histopathology. In two patients, despite review, it was impossible
to identify which was present. The median survival for the patients
with heterologous tumours was 8.5 months and for homologous
tumours it was 8.9 months. The 1-year survival was 42% in the
former group and 50% in the latter group. There was no significant
difference in survival between the groups (P¼0.28).
Treatment
Chemotherapy was administered to 32 of the 40 cases (80%) and
the remaining eight cases were either deemed too unwell or died
before it could be given. Of the 32 patients who received
chemotherapy, 26 (81%) cases received platinum-based regimens,
mainly using carboplatin either alone or with ifosfamide (see Table
2). The dose of carboplatin given was calculated using an area
under the curve of 6 when used as a single agent and 5 when used
in combination, and ifosfamide was given at a dose of 3gm
 2 on
days 1–3. Both chemotherapy regimens were given once every 3
weeks. Only one patient received a taxane because they were
initially thought to have the more common type of ovarian
adenocarcinoma. Of the 32 patients who received at least one cycle
of chemotherapy, three out of 32 (9.4%) achieved a complete
clinical and radiological response, 10 out of 32 (31%) achieved a
partial response while in five out of 32 (16%) the disease remained
Table 1 Patient characteristics
Median age (range) 65 (45–86)
Median KP (range) 70 (30–90)
FIGO stage I 1
FIGO stage II 6
FIGO stage III 17
FIGO stage IV 15
Unknown stage 1
No residual disease post surgery 4
Microscopic residual disease (o2cm) 9
Bulk residual disease (>2cm) 27
Homologous tumour 14
Heterologous tumour 24
Unknown type of tumour 2
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Figure 1 Relation between bulk residual disease and survival. The
number of patients at risk are shown below the x-axis. The dotted line
represents patients with complete cytoreduction and those with minimal
residual disease. The solid line represents patients with bulky residual
disease.
Table 2 Chemotherapy regimens
Platinum containing chemotherapy regimens
Carboplatin and ifosfamide (Carbo-I) 9
Carboplatin (Carbo) 9
Cyclophosphamide, adriamycin and cisplatin (CAP) 3
Carboplatin and cyclophosphamide (Carbo-C) 2
Epirubicin, carboplatin and 5FU (E-Carbo-F) 1
Epirubicin, cisplatin and 5FU (ECF) 1
Taxol and Carboplatin (T-Carbo) 1
Other chemotherapy regimens
Doxorubicin (A) 2
Doxorubicin and cyclophosphamide (AC) 1
Cyclophosphamide (IV) 1
Cyclophosphamide (oral) 1
Melphalan 1
Total 32
Carbo-I=carboplatin AUC of 5 and ifosfamide 3gm
 2 D1-3; Carbo=carboplatin
AUC of 6; CAP=cyclophosphamide 750mgm
 2; doxorubicin 50mgm
 2 and
cisplatin 50mgm
 2; Carbo-C=carboplatin AUC of 5 and cyclophosphamide
600mgm
 2; E-Carbo-F=epirubicin 50mgm
 2, carboplatin AUC of 5 and 5FU
1.2m
 2, ECF=epirubicin 50mgm
 2, cisplatin 70mgm
 2 and 5FU 200mgm
 2/day
via a pump for 4 weeks repeated monthly; T-Carbo=taxol 175mgm
 2 and
carboplatin AUC of 5; A=doxorubicin 75mgm
 2, AC=doxorubicin 60mgm
 2 and
cyclophosphamide 600mgm
 2; cyclophosphamide=600mgm
 2 (IV) once every 3
weeks and 50mg TDS for 14days monthly; melphalan=5mg for 5 days six times
weekly. All chemotherapy were given once every 3 weeks unless stated.
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the 32 patients had disease that was not assessable as three died
after the first cycle and one patient had FIGO stage Ic disease and
had no radiologically detectable residual disease. Interestingly, one
patient with stage III disease who received only one cycle of
chemotherapy because of intercurrent illness appeared to have
achieved a partial response on subsequent CT scans and is still
alive 14 months later. For the six patients who received
nonplatinum-based chemotherapy, two patients achieved a PR,
three had progressive disease and one died after the first cycle and
so was unassessable.
Progression-free survival and the treatment of recurrent
disease
Of the 19 patients who achieved either a complete response (CR) or
partial response (PR) or static disease (including the patient with
stage Ic), the median survival was 29.6 months and the time to
recurrence (from date of operation) was 22.6 months. One patient
was treated initially with pelvic radiotherapy and received
chemotherapy later in the course of her disease. Four patients
received radiotherapy for symptomatic residual disease (two for
first recurrence and two for second recurrence) without evidence
of response. Six patients underwent a further laparotomy after
chemotherapy. Three of these patients had disease that was
initially inoperable, but had a good response to chemotherapy and
underwent definitive surgery that included a total hysterectomy,
bilateral salpingo-oophorectomy and omentectomy. Of the other
three, one underwent surgery for progressive disease immediately
post chemotherapy, one at relapse several months later and the
final patient had been treated elsewhere initially with oral
chemotherapy, and had relapsed and undergone repeat laparo-
tomy prior to referral to our centre. All three of these patients had
initially had adequate debulking surgery.
Overall survival
Currently seven patients are still alive, one with cancer, and there
have been two intercurrent deaths. The other 31 patients have died
of their disease. The overall censored median survival was 8.7
months and the median follow-up period from diagnosis was 34
months. The stage-related survival curves are shown in Figure 2.
There was no significant difference found between the survival
curves for stages I and II vs stages III and IV (P¼0.16).
DISCUSSION
This is the largest reported series of carcinosarcoma of the ovary.
The 40 cases made up 1.3% of the cases of malignant ovarian
carcinoma in this institute over a 10-year period. The median age
and stage at operation were similar to previous studies (Chang
et al, 1995; Terada et al, 1989; Sreenan and Hart, 1995). It has been
suggested that heterologous tumours may be more advanced and
have a worse prognosis (Calame and Schaberg, 1989), but this was
not confirmed by our results.
It is well known in ovarian carcinoma that bulk residual disease
is associated with a worse survival, but this has not been shown
statistically in ovarian carcinosarcoma before. Our data show a
statistically significant survival benefit for women who have
optimum cytoreduction after surgery.
The response rate of 41% in patients treated with chemotherapy
compares favourably with the published data of 35–47% (Prendi-
ville et al, 1994; Chang et al, 1995). The response rate in the 26
patients who received platinum-based chemotherapy was 42% and
for other chemotherapy regimens it was 33%. Many different
chemotherapy regimens were used reflecting the uncertainty of
treatment for this malignancy. It was noteworthy that of the nine
patients who were initially planned to receive the more toxic
sarcoma-type chemotherapy with ifosfamide and carboplatin, six
of them only tolerated one cycle with ifosfamide, and then either
received no further chemotherapy or were treated with carboplatin
alone. This reflects the poor general condition (median KP was 70)
of these women. It was also interesting that responses to second-
and third-line chemotherapy were observed particularly with a
single-agent carboplatin.
The role of therapeutic radiotherapy is not established. In this
series radiotherapy was given to only five patients – all for
different indications and with no evidence of CRs. Three of these
patients died within 6 months of radiotherapy and the other two
relapsed less than a year post-treatment.
The overall median survival of 8.7 months is still poor as
previously reported. The 1-year survival was 40% and the 5-year
survival was 7.5% as compared to approximately 15–40% 5-year
survival in epithelial ovarian carcinoma. As can be seen from the
survival curves (Figures 1 and 2), many patients die within the first
few months of surgery and do not complete a course of
chemotherapy, but there are a substantial subgroup of patients
who respond to chemotherapy and appear to have a much better
survival. Therefore, all patients with this diagnosis should be
referred to a specialist centre for treatment, ideally within a
defined protocol, although the optimal chemotherapy has yet to be
fully identified. Clinical trials for carcinosarcoma of the ovary
would be beneficial but may have difficulty accruing because of the
rarity of the disease.
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Figure 2 Relation between stage and survival. Survival was classified
according to stages 1/2 and 3/4. The number of patients at risk are shown
below the x-axis. The dotted line represents patients with stage 1 or 2
disease. The solid line represents patients with stages 3 and 4 disease. The
stage in one patient could not be determined.
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